Journal of Clinical Oncology
Articles in this Issue
Advancing evidence-based NSCLC testing and treatment across academic and community-based settings.
8621 Background: Comprehensive testing for guideline-recommended driver mutations in advanced non-small cell lung cancer (aNSCLC) remains underutilized....
Real world characteristics of stages II-III NSCLC patients (pts) who initiate neoadjuvant chemo-immunotherapy (NACT-I) and do not undergo surgical resection.
8019 Background: Neoadjuvant and perioperative chemo-immunotherapy studies report 15%-20% of pts initiating NACT-I do not...
SIM0270 in combination with palbociclib in patients with ER+/ HER2- advanced breast cancer: The phase Ib study.
1068 Background: SIM0270 is a highly potent oral selective estrogen receptor degrader (SERD) which has shown ER degradation and robust antitumor activity...
CTC landscape during HCC immunotherapy.
4112 Background: The treatment of hepatocellular carcinoma (HCC), the third leading cause of global cancer death, has significantly improved with the adve...
Gene set enrichment analysis of oral cavity carcinoma to identify pathways associated with lymph node metastasis.
e18108 Background: Oral cavity cancers (OCC) have a high propensity for lymph node metastasis (LNM), and level one evidence supports disease-free and over...
Association between dietary cholesterol, serum lipids, and cancer-specific mortality in U.S. adults.
e22609 Background: The relationship between dietary cholesterol and its impact on serum lipids and health outcomes remains a topic of debate. This study a...
Breast cancer screening mammography among transgender and gender diverse (TGD) individuals: A nationwide study of >10,000 TGD individuals.
1530 Background: Regular breast cancer screening reduces mortality. The American College of Radiology (ACR) recommends annual screening mammography for as...
The effect of a vertically integrated health system on the disparity of socioeconomic status seen in cancer stage at presentation.
1617 Background: Earlier stage of diagnosis may lead to more curable disease and less intensive treatment. Vertically integrated health care systems throu...
Advanced lung cancer inflammation index (ALI) as a prognostic marker for locally advanced and metastatic cancer: A prospective study.
e20513 Background: We developed ALI as a prognostic marker (ALI <18 = poor prognosis, ALI ≥ 18=good prognosis) for patients with metastatic non-small c...
A qualitative analysis of uncertainty in cancer diagnosis and treatment.
e24065 Background: Uncertainty is an inherent part of patients’ cancer experiences and can affect their psychological well-being; however, most research t...
Real world outcomes of patients treated with tarlatamab in extensive stage small cell lung cancer.
e20120 Background: In May 2024, the FDA approved tarlatamab, a Delta-like ligand (DLL3)/CD3-targeted bispecific T-cell engager, for patients with extensiv...
Risk factors in adolescents and young adults associated with hepatobiliary cancer: A review.
e16332 Background: Incidence of cancer among adolescents and young adults (AYA) ages 15-39 has risen. Hepatobiliary cancers (HBC), including hepatocellula...
Biological determinants of immune exclusion in non-small cell lung cancer: An analysis of the precision medicine BIP study.
2636 Background: Immune exclusion has been associated with resistance to immunotherapy in NSCLC. However, its biological determinants remain largely unkno...
Predictors of overall survival in patients with brain metastases from HER2+ breast cancer.
2037 Background: Predictors of overall survival (OS) after brain metastasis (BM) in HER2-positive breast cancer (BC) are not well characterized. This stud...
Comparative analysis of immunohistochemistry and imaging mass cytometry technologies for detection of clinical biomarkers in cancer tissues.
e14628 Background: Detecting clinically relevant biomarkers in cancer tissues provides key insights into the unique tumor characteristics of patients, all...
Lacutamab in patients with relapsed and refractory Sézary syndrome: Long term follow-up from the TELLOMAK phase 2 trial.
2522 Background: Sézary syndrome (SS) is a rare and aggressive cutaneous T-cell lymphoma, which commonly expresses KIR3DL2, a killer immunoglobulin-like r...
Circulating CD28-KLRG1+CD8+ T cells as prognostic indicators in advanced NSCLC chemoimmunotherapy.
8553 Background: Chemoimmunotherapy has become the standard first-line treatment for advanced non-small cell lung cancer (NSCLC), but patient responses va...
Clinical impact of single nucleotide polymorphisms (SNPs) in <i>PDCD1</i> in patients with non-small cell lung cancer (NSCLC) receiving anti-PD1 immunotherapy.
e20625 Background: Lung cancer is the leading cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for approximate...
Clinical features and outcomes of patients with synchronous cancers in West Virginia.
e23287 Background: Synchronous cancers, defined as ≥2 separate malignancies diagnosed in the same individual within 6 months, pose unique clinical challen...
Do health care providers offer advice to adolescents about nicotine-containing product use?
10530 Background: Use of tobacco and other nicotine-containing products is a major preventable cause of cancer. Most individuals initiate nicotine product...
Knowledge, practice, and attitude on human papillomavirus and cervical cancer among medical students in Armenia: Cross-sectional study.
e22502 Background: Cervical Cancer (CC) is a huge burden worldwide, especially in developing countries. CC incidence rates tend to escalate in Armenia inc...
Survival disparities with racial, age, and sex differences in myelodysplastic syndromes: A Surveillance, Epidemiology, and End Results analysis (2014-2020).
e18576 Background: Myelodysplastic syndromes (MDS) are a diverse group of clonal hematologic disorders characterized by ineffective hematopoiesis and vari...
Identifying peripheral cancer-associated TCR signals for the early-detection of lung cancer.
2566 Background: Tumor-associated antigens and neoantigens play a critical role in eliciting anti-tumor immune responses, leading to a significant amplifi...
Prognostic significance of pathological response in unresectable hepatocellular carcinoma treated with immune checkpoint inhibitor-based conversion therapy.
4140 Background: Immune checkpoint inhibitor (ICI)-based conversion treatment is increasingly utilized for patients with initially unresectable hepatocell...
Evaluating the safety and effectiveness of cemiplimab in combination with platinum-doublet chemotherapy by demographic characteristics in first-line treatment of advanced non-small cell lung cancer: An ongoing multi-database real world evidence study in US patients.
e20572 Background: The Food and Drug Administration (FDA) has issued guidance urging sponsors to encourage inclusion of underrepresented populations in cl...